38 results match your criteria International Journal of Clinical Rheumatology[Journal]

  • Page 1 of 1

Association of weight loss with improved disease activity in patients with rheumatoid arthritis: A retrospective analysis using electronic medical record data.

Int J Clin Rheumtol 2018 ;13(1):1-10

Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA.

Objective: To evaluate the association between weight loss and rheumatoid arthritis (RA) disease activity.

Methods: We conducted a retrospective cohort study of RA patients seen at routine clinic visits at an academic medical center, 2012-2015. We included patients who had ≥2 clinical disease activity index (CDAI) measures. Read More

View Article

Download full-text PDF

Source
http://www.openaccessjournals.com/articles/association-of-we
Publisher Site
http://dx.doi.org/10.4172/1758-4272.1000154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875117PMC
January 2018
18 Reads

Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis.

Int J Clin Rheumtol 2015 Dec;10(6):451-459

Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada.

Numerous studies have suggested a link between psoriatic arthritis (PsA) and comorbidities, in particular cardiovascular disease and metabolic comorbidities such as diabetes. The co-existence of these comorbidities is likely the result of systemic inflammation. In order to improve the health of patients with PsA and provide optimal care, these comorbidities must be addressed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.15.45DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847747PMC
December 2015
10 Reads

Improving treatment adherence in patients with rheumatoid arthritis: what are the options?

Int J Clin Rheumtol 2015 Oct;10(5):345-356

Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Low adherence to therapeutic regimens is a prevalent and persistent healthcare problem, particularly for patients with chronic disorders. Many patients with rheumatoid arthritis (RA) show inadequate therapeutic adherence resulting in poor health outcomes. Reasons for nonadherence can be unintentional or intentional. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.15.39DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826730PMC
October 2015
10 Reads

Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions.

Int J Clin Rheumtol 2015 Oct;10(5):365-381

Department of Medicine, Stanford University, Stanford, CA 94305, USA.

Atherosclerosis is a complex inflammatory disease involving aberrant immune and tissue healing responses, which begins with endothelial dysfunction and ends with plaque development, instability and rupture. The increased risk for coronary artery disease in patients with rheumatologic diseases highlights how aberrancy in the innate and adaptive immune system may be central to development of both disease states and that atherosclerosis may be on a spectrum of immune-mediated conditions. Recognition of the tight association between chronic inflammatory disease and complications of atherosclerosis will impact the understanding of underlying pathogenic mechanisms and change diagnostic and therapeutic approaches in patients with rheumatologic syndromes as well as patients with coronary artery disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.15.33DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814165PMC
October 2015
8 Reads

Autoimmune or Autoiflammatory? Bad to the Bone.

Int J Clin Rheumtol 2015;10(1):5-7

Department of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis CA ; Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children Northern California, Sacramento, CA, 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.15.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570489PMC
January 2015
10 Reads

Perceptions of physical activity engagement among adults with rheumatoid arthritis and rheumatologists.

Int J Clin Rheumtol 2015;10(2):67-77

Department of Physical Therapy, Movement & Rehabilitation Sciences, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Avenue, 301 C RB, Boston, MA 02115, USA.

Aim: Physical activity (PA) among adults with rheumatoid arthritis (RA) is suboptimal. This study assessed PA motivations and perceptions in adults with RA and rheumatologists.

Methods: Patients and rheumatologists participated in structured interviews led by a behavioral scientist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.15.3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460984PMC
January 2015
6 Reads

Future directions for the management of pain in osteoarthritis.

Int J Clin Rheumtol 2014 Apr;9(2):197-276

Osteoarthritis (OA) is the predominant form of arthritis worldwide, resulting in a high degree of functional impairment and reduced quality of life owing to chronic pain. To date, there are no treatments that are known to modify disease progression of OA in the long term. Current treatments are largely based on the modulation of pain, including NSAIDs, opiates and, more recently, centrally acting pharmacotherapies to avert pain. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089899PMC
April 2014
4 Reads

Systemic lupus erythematosus diagnostics in the 'omics' era.

Int J Clin Rheumtol 2013 Dec;8(6):671-687

Department of Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Room 2018, Houston, TX 77204, USA.

Systemic lupus erythematosus is a complex autoimmune disease affecting multiple organ systems. Currently, diagnosis relies upon meeting at least four out of eleven criteria outlined by the ACR. The scientific community actively pursues discovery of novel diagnostics in the hope of better identifying susceptible individuals in early stages of disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.13.59DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029501PMC
December 2013
8 Reads

Cytomegalovirus infection in childhood-onset systemic lupus erythematosus.

Int J Clin Rheumtol 2013 Feb;8(1):137-146

Department of Pediatrics, Hospital for Sick Children & University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada ; Division of Rheumatology, Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.

Systemic lupus erythematosus (SLE) is a multisystem disease with significant morbidity and even mortality. (CMV) is a ubiquitous herpesvirus that, similar to SLE, can also lead to significant morbidity and mortality in the immunocompromised host. The relationship between SLE and CMV is complex, with observations suggesting that CMV induces the autoimmunity of SLE in addition to occurring in the immunocompromised host with known SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.12.82DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920748PMC
February 2013
8 Reads

The important role of CNS facilitation and inhibition for chronic pain.

Authors:
Roland Staud

Int J Clin Rheumtol 2013 Dec;8(6):639-646

Division of Rheumatology & Clinical Immunology, University of Florida, PO Box 100221, Gainesville, FL 32610-0221, USA, Tel.: +1 352 273 9681.

Multiple studies have demonstrated that the pain experience among individuals is highly variable. Even under circumstances where the tissue injuries are similar, individual pain experiences may vary drastically. However, this individual difference in pain sensitivity is not only related to sensitivity of peripheral pain receptors, but also to variability in CNS pain processing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.13.57DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904391PMC
December 2013
8 Reads

Occurrence of gout in rheumatoid arthritis: it does happen! A population-based study.

Int J Clin Rheumtol 2013 Aug;8(4):433-437

Division of Rheumatology, Department of Medicine, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA ; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Aim: It has been a popular belief that gout does not typically occur in patients with rheumatoid arthritis (RA). Our aim was to assess the occurrence, prevalence, clinical presentation and possible risk factors for gout in patients with RA.

Patients & Methods: We retrospectively reviewed a population-based incidence cohort of patients who fulfilled 1987 ACR criteria for RA between 1980 and 2007. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.13.45DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891477PMC
August 2013
5 Reads

Genetics of the type I interferon pathway in systemic lupus erythematosus.

Int J Clin Rheumtol 2013 Dec;8(6)

Division of Rheumatology, Department of Immunology, Mayo Clinic, 200 1st Street SW, Guggenheim Building 3-42, Rochester, MN 55905, USA.

Genetic studies of systemic lupus erythematosus (SLE) have been successful, identifying numerous risk factors for human disease. While the list is not yet complete, it is clear that important immune system pathways are represented, one of which being type I interferon (IFN). Circulating type I IFN levels are high in SLE patients and this IFN pathway activation is heritable in families with SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.13.58DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885171PMC
December 2013
7 Reads

Sphingosine kinase and sphingosine-1-phosphate: regulators in autoimmune and inflammatory disease.

Authors:
Ashley J Snider

Int J Clin Rheumtol 2013 Aug;8(4)

Northport Veterans Affairs Medical Center, Northport, NY 11768, USA and Department of Medicine, Stony Brook University, 100 Nicolls Road, Health Sciences Center L15-023, Stony Brook, NY 11794, USA.

Sphingolipids and their metabolizing enzymes are beginning to be recognized as critical mediators in biological processes, specifically in inflammation and autoimmunity. Sphingosine kinases (SKs) and their lipid product sphingosine-1-phosphate (S1P) play essential roles in inflammatory signaling processes, as well as disease development and progression. SKs can be activated by numerous growth factors and cytokines, including TNF-α and IL-1β, leading to the generation of S1P. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.13.40DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883358PMC
August 2013
5 Reads

Understanding why cognitive-behavioral therapy is an effective treatment for adolescents with juvenile fibromyalgia.

Int J Clin Rheumtol 2013 Apr;8(2)

Division of Behavioral Medicine & Clinical Psychology, Cincinnat Children's Hospital Medical Center, Cincinnat, OH 45229, USA ; Department of Pediatrics, University of Cincinnat College of Medicine, Cincinnat, OH, USA.

Recent studies have demonstrated that cognitive-behavioral therapy (CBT) is an effective treatment for children and adolescents with juvenile fibromyalgia. Unfortunately, the specific psychological changes that occur during treatment that explain why CBT works are not well understood. Historically, the increased use of specific coping strategies learned during CBT was thought to be the primary reason for why CBT was effective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/IJR.13.3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885254PMC
April 2013
30 Reads

The lung may play a role in the pathogenesis of rheumatoid arthritis.

Int J Clin Rheumtol 2014;9(3):295-309

University of Colorado School of Medicine, Aurora, CO, USA.

Multiple studies have identified strong associations between the lung and rheumatoid arthritis (RA). Such studies identify a high prevalence of lung disease, both airways and parenchymal disease, in subjects with clinically classifiable RA. It has been suggested that lung disease in RA results from targeting of the lung from circulating autoimmunity or other factors such as medications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.14.23DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469280PMC
January 2014
5 Reads

Updates on the risk markers and outcomes of severe juvenile idiopathic arthritis-associated uveitis.

Int J Clin Rheumtol 2013 Feb;8(1)

Emory University, Atlanta, GA 30322, USA ; Children's Healthcare of Atlanta, Atlanta, GA, USA.

Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis, which is the most common systemic cause of uveitis in children. Known risk factors for uveitis include antinuclear antibody seropositivity, young age of arthritis onset, specific juvenile idiopathic arthritis subtype and short duration of disease. Risk markers for severe ocular disease include gender, age and complications at initial visit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.12.83DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810987PMC
February 2013
6 Reads

Recommendations and the state of the evidence for physical activity interventions for adults with rheumatoid arthritis: 2007 to present.

Int J Clin Rheumtol 2012 Oct;7(5):489-503

Department of Physical Therapy, School of Health Professions, Bouve College of Health Sciences, Northeastern University, 6 Robinson Hall, Room 301C, 360 Huntington Avenue, Boston, MA 02115, USA ; Baylor University, Waco, TX, USA ; Harvard Medical School, Boston, MA, USA.

Patients with rheumatoid arthritis (RA) are twice as likely as their healthy peers to suffer from cardiovascular disease. RA is also a major cause of disability and reduced quality of life. Clinical trials of exercise and physical activity interventions demonstrate positive effects on muscle strength, function, aerobic capacity, mood and disability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.12.53DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607375PMC
October 2012
6 Reads

Serologic features of primary Sjögren's syndrome: clinical and prognostic correlation.

Int J Clin Rheumtol 2012 Dec;7(6):651-659

Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR IMSS, 10 Poniente 2721, Puebla, Mexico ; Department of Rheumatology, School of Medicine, BUAP, Mexico.

Sjögren's syndrome (SS) is a chronic inflammatory systemic autoimmune disease. The disease spectrum extends from sicca syndrome to systemic involvement and extraglandular manifestations, and SS may be associated with malignancies, especially non-Hodgkin's lymphoma. Patients with SS present a broad spectrum of serologic features. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.12.64DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602968PMC
December 2012
11 Reads

The molecular basis for disease phenotype in chronic Chlamydia-induced arthritis.

Int J Clin Rheumtol 2012 Dec;7(6):627-640

Department of Medicine/Division of Rheumatology, University of South Florida College of Medicine, Tampa, FL, USA.

Genital Chlamydia trachomatis infections can elicit an inflammatory arthritis in some individuals, and recent surprising studies have demonstrated that only ocular (trachoma) strains, not genital strains, of the organism are present in the synovial tissues of patients with the disease. This observation suggests an explanation for the small proportion of genitally-infected patients who develop Chlamydia-induced arthritis. Other recent studies have begun to identify the specific chlamydial gene products that elicit the synovial inflammatory response during both active and quiescent disease, although much more study will be required to complete the understanding of that complex process of host-pathogen interaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.12.65DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579635PMC
December 2012
12 Reads

Accelerated atherosclerosis in SLE: mechanisms and prevention approaches.

Int J Clin Rheumtol 2012 Oct;7(5):527-539

Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disease characterized by increased serum autoantibody levels and tissue damage. With improved diagnosis and more effective treatment of the resultant kidney disease, accelerated atherosclerosis has become a major cause of morbidity in patients suffering from SLE. Although the exact mechanisms for SLE-accelerated atherosclerosis are unknown, multiple factors have been established as potential players in this process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.12.46DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963493PMC
October 2012
22 Reads

Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis?

Int J Clin Rheumtol 2012 Apr;7(2):159-166

Section of Rheumatology, Department of Medicine, Temple University School of Medicine, 3322 North Broad St., Room 205, Philadelphia, PA 19140, USA.

The continued efficacy of B-cell depletion in rheumatoid arthritis (RA) depends on repeated cycles of anti-CD20 treatment to maintain low levels of B cells. It is surprising that this significant manipulation of the humoral immune system is remarkably safe with repeated treatment and that rates of adverse effects remain stable, and may even decline, over subsequent courses. Although responses to vaccines and probably to new antigens are diminished, adaptive immunity nevertheless functions adequately despite markedly restricted B-cell numbers. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392126PMC
April 2012
7 Reads

Fatigue in systemic lupus erythematosus.

Int J Clin Rheumtol 2012 Apr;7(2):217-227

Division of Rheumatology, Northwestern University, 240 E. Huron St. McGaw M300, Chicago, IL 6061, USA.

Systemic lupus erythematosus is a chronic inflammatory autoimmune disease often characterized by fatigue, with significant effects on physical functioning and wellbeing. The definition, prevalence and factors associated with fatigue, including physical activity, obesity, sleep, depression, anxiety, mood, cognitive dysfunction, vitamin D deficiency/insufficiency, pain, effects of medications and comorbidities, as well as potential therapeutic options of fatigue in the systemic lupus erythematosus population are reviewed. Due to variability in the reliability and validity of various fatigue measures used in clinical studies, clinical trial data have been challenging to interpret. Read More

View Article

Download full-text PDF

Source
http://www.futuremedicine.com/doi/abs/10.2217/ijr.12.4
Publisher Site
http://dx.doi.org/10.2217/IJR.12.4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380630PMC
April 2012
10 Reads

Healthcare quality in systemic lupus erythematosus: using Donabedian's conceptual framework to understand what we know.

Int J Clin Rheumtol 2012 Feb;7(1):95-107

University of California, San Francisco, Department of Pediatrics, Division of Rheumatology, 3333 California Street, Box 0920, San Francisco, CA 94143, USA.

Healthcare quality improvement has the potential to reduce the striking disparities in health outcomes among patients with systemic lupus erythematosus (SLE). Donabedian's framework for assessment of healthcare quality, which divides factors impacting quality into structures, processes and outcomes, provides a theoretical framework for research and interventions in quality improvement. This review applies Donabedian's model to current research describing quality of care in SLE, highlighting structures and processes that may lead to improved outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.11.65DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308354PMC
February 2012
8 Reads

Depression in patients with rheumatoid arthritis: description, causes and mechanisms.

Int J Clin Rheumtol 2011 ;6(6):617-623

Department of Medicine, University of California, San Francisco, CA, USA.

Two sets of contributory factors to depression among patients with rheumatoid arthritis (RA) are generally examined - the social context of the individual and the biologic disease state of that person's RA. This article will review the evidence for both. RA affects patients both physically and psychologically. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/IJR.11.6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247620PMC
January 2011
4 Reads

Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents.

Int J Clin Rheumtol 2011 Aug;6(4):423-439

Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder of an unclearly determined etiology. Past studies, both epidemiological and biological, have implicated epigenetic influences in disease etiology and pathogenesis. Epigenetics describes changes in gene expression not linked to alterations in the underlying genomic sequence, and is most often typified by three modifications: methylation of DNA, addition of various side chains to histone groups and transcriptional regulation via short ncRNA sequences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.11.32DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241218PMC
August 2011
6 Reads

Combination antibiotics for the treatment of Chlamydia-induced reactive arthritis: is a cure in sight?

Int J Clin Rheumtol 2011 Jun;6(3):333-345

Department of Internal Medicine, Division of Rheumatology, University of South Florida, Tampa, FL, USA.

The inflammatory arthritis that develops in some patients subsequent to urogenital infection by the obligate intracellular bacterial pathogen Chlamydia trachomatis, and that induced subsequent to pulmonary infection with C. pneumoniae, both have proved difficult to treat in either their acute or chronic forms. Over the last two decades, molecular genetic and other studies of these pathogens have provided a good deal of information regarding their metabolic and genetic structures, as well as the detailed means by which they interact with their host cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.11.20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155888PMC
June 2011
6 Reads

Optical imaging of rheumatoid arthritis.

Int J Clin Rheumtol 2011 Feb;6(1):67-75

Department of Radiology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

Optical Imaging (OI) for rheumatoid arthritis is a novel imaging modality. With the high number of people affected by this disease, especially in western countries, the availability of OI as an early diagnostic imaging method is clinically highly relevant. In this article we describe the current techniques of OI and discuss potential future applications of this promising technology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.10.105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151026PMC
February 2011
10 Reads

Pathophysiological mechanisms in antiphospholipid syndrome.

Int J Clin Rheumtol 2011 Apr;6(2):157-171

Department of Internal Medicine, Division of Rheumatology, University of texas medical branch, Galveston, TX, USA.

Antiphospholipid syndrome is a systemic autoimmune disease associated with thrombosis and recurrent fetal loss in the setting of detectable antiphospholipid (aPL) antibodies. The major antigenic target has been identifed as β-glycoprotein I (βGPI), which mediates binding of aPL antibodies to target cells including endothelial cells, monocytes, platelets and trophoblasts, leading to prothrombotic and proinfammatory changes that ultimately result in thrombosis and fetal loss. This article summarizes recent insights into the role of βGPI in normal hemostasis, interactions between aPL antibodies, βGPI and cell-surface molecules, molecular prothrombotic and proinfammatory changes induced by aPL antibodies and pathogenic changes leading to fetal loss in antiphospholipid syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.11.9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593246PMC
April 2011
11 Reads

Biologic agents in systemic vasculitis.

Int J Clin Rheumtol 2011 ;6(4):453-462

5501 Hopkins Bayview Circle, JHAAC, Room 1B.1A, Johns Hopkins University Division of Rheumatology, MD 21224, USA.

The treatment of systemic necrotizing vasculitis has made great strides in both efficacy and outcomes. Standard therapies, however, are associated with numerous side effects, and not all patients will respond to conventional immunosuppression. These realities have prompted the search for safer and more efficacious treatments, most notably among biologic agents. Read More

View Article

Download full-text PDF

Source
http://www.futuremedicine.com/doi/abs/10.2217/ijr.11.29
Publisher Site
http://dx.doi.org/10.2217/IJR.11.29DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684397PMC
January 2011
8 Reads

The potential importance of Toll-like receptors in ankylosing spondylitis.

Int J Clin Rheumtol 2011 ;6(6):649-654

Division of Rheumatology, Department of Internal Medicine, 6431 Fannin, MSB 5.270, Houston, TX 77030, USA.

Cells involved in innate immunity scan for pathogens via extracellular and intracellular (endosomal) pattern recognition receptors (PRRs). Engagement of PRRs by a specific ligand results in downstream activation of intracellular inflammatory cascades. There is emerging evidence indicating that one class of PRR, the Toll-like receptor (TLR) plays a potential role in the pathogenesis of spondyloarthropathies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/IJR.11.61DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290398PMC
January 2011
3 Reads

Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus.

Int J Clin Rheumtol 2010 Jun;5(3):313-326

The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

Treatment adherence is critical in the management of rheumatic diseases. Recent advances in therapy for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are promising, although the impact on quality of life may be limited due to nonadherence. Databases including Ovid Medline, Scopus and the Epub-ahead-of-print subset of PubMed were searched for the period of the last 10 years using combined keywords patient compliance, medication adherence, disease modifying antirheumatic drug (DMARD), rheumatoid arthritis and systemic lupus erythematosus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.10.15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910438PMC
June 2010
5 Reads

Joint aging and chondrocyte cell death.

Int J Clin Rheumtol 2010 Apr;5(2):199-214

Articular cartilage extracellular matrix and cell function change with age and are considered to be the most important factors in the development and progression of osteoarthritis. The multifaceted nature of joint disease indicates that the contribution of cell death can be an important factor at early and late stages of osteoarthritis. Therefore, the pharmacologic inhibition of cell death is likely to be clinically valuable at any stage of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.10.3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909784PMC
April 2010
6 Reads

Rates of bone loss in young adult males.

Int J Clin Rheumtol 2010 Apr;5(2):215-228

EA Martin Program, Box 506, Wecota Hall, South Dakota State University, Brookings, SD 57007, USA, Tel.: +1 605 688 4645, ,

Osteoporosis-related fractures occur more frequently in women compared with men, but mortality is greater in men compared with women. Peak bone mass is a significant predictor of osteoporosis and fracture risk; therefore, it is important to optimize peak bone mass during young adulthood. Several recent longitudinal studies, which are summarized in this article, have investigated bone changes among young men. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.10.7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897064PMC
April 2010
6 Reads

Current options for nonsurgical management of carpal tunnel syndrome.

Int J Clin Rheumtol 2010 Feb;5(1):129-142

Carpal tunnel syndrome (CTS) is the most common of the entrapment neuropathies. Surgical decompression is commonly performed and has traditionally been considered the defnitive treatment for CTS. Conservative treatment options include physical therapy, bracing, steroid injections and alternative medicine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/IJR.09.63DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871765PMC
February 2010
5 Reads

Management of cardiovascular complications in systemic lupus erythematosus.

Int J Clin Rheumtol 2010 Feb;5(1):75-100

Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Patients with SLE have an excess risk compared with the general population; this is particularly pronounced in younger women with SLE who have an excess risk of over 50-fold compared with population controls. There is a higher prevalence of subclinical atherosclerosis in patients with SLE compared with controls, as demonstrated by a variety of imaging modalities discussed in this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.09.73DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2839248PMC
February 2010
6 Reads

Infection in systemic lupus erythematosus: friend or foe?

Int J Clin Rheumtol 2010 Feb;5(1):59-74

Division of Rheumatology, Department of Medicine State University of New York, College of Medicine 750 East Adams Street Syracuse, New York 13210, USA.

Infectious agents have long been implicated in the pathogenesis of systemic lupus erythematosus. Common viruses, such as the Epstein-Barr virus, transfusion transmitted virus, parvovirus and cytomegalovirus, have an increased prevalence in patients with systemic lupus erythematosus. They may contribute to disease pathogenesis through triggering autoimmunity via structural or functional molecular mimicry, encoding proteins that induce cross-reactive immune responses to self antigens or modulate antigen processing, activation, or apoptosis of B and T cells, macrophages or dendritic cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijr.09.72DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830655PMC
February 2010
5 Reads

Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.

Int J Clin Rheumtol 2010;5(3):355-370

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21224.

Digital ischemia is a painful and often disfiguring event. Such an ischemic event often leads to tissue loss and can significantly affect the patient's quality of life. Digital ischemia can be secondary to a vasculopathy, vasculitis, embolic disease, trauma, or extrinsic vascular compression. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624318PMC
January 2010
8 Reads

Potential implications of cell therapy for osteogenesis imperfecta.

Int J Clin Rheumtol 2009 Feb;4(1):57-66

Osteogenesis imperfecta (OI) is a brittle-bone disease whose hallmark is bone fragility. Since the disease is genetic, there is currently no available cure. Several pharmacological agents have been tried with not much success, except the recent use of bisphosphonates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/17584272.4.1.57DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873227PMC
February 2009
6 Reads
  • Page 1 of 1